GlassScriptPhysician profile
Jean Wany
NPI 1376938803
$3,034.02
in general payments reported to CMS, 2019-2025
26 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $467 · 2023: $560 · 2024: $473 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.39 | 2021-2024 | |
| Novo Nordisk INC | $566.84 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $316.40 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $293.22 | 2021-2025 | |
| Amarin Pharma, INC. | $149.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.54 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $107.23 | 2021-2025 | Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $106.82 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $103.63 | 2021-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $87.54 | 2023-2025 | Cologuard Collection Kit |
| Global Blood Therapeutics, INC. | $81.50 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.61 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $47.54 | 2024-2025 | Farxiga |
| Shield Therapeutics INC | $39.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $37.77 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.47 | 2021 | |
| Genzyme Corporation | $31.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.87 | 2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $24.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.68 | 2021 | |
| Renalytix Ai, INC. | $22.49 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Kowa Pharmaceuticals America, INC. | $22.14 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.19 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Wany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.